Fulcrum Therapeutics tanks as muscle disorder drug fails in late-stage study

Fulcrum Therapeutics

12/09/2024 12:54

** Shares of drug developer Fulcrum Therapeutics  FULC.O 
plunge 70.62% to $2.60 premarket
    ** Co says its experimental drug to treat a genetic muscle
disorder failed to meet the main goal in a late-stage study
    ** Co was testing its oral drug, losmapimod, in 260 patients
with facioscapulohumeral muscular dystrophy (FSHD) who received
either the therapy or a placebo for 48 weeks
    ** Adds will suspend future losmapimod development
    ** FSHD is a rare genetic muscle disease in which the
muscles of the face, shoulder blades, and upper arms are among
the most affected
    ** Up to last close, stock up ~31% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))